Clinical Trial Update: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 1/2 study evaluating INO-5401 and INO-9012 delivered by electroporation with cemiplimab in newly diagnosed glioblastom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• INO-5401 (INO-5401)
• INO-9012 (INO-9012)

Snippet

Sponsor: Inovio Pharmaceuticals | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING